Klaria Pharma Holding AB
Klaria Pharma Holding AB (publ.), a pharmaceutical company develops and commercializes medication for migraine and cancer related pain, and opioid overdose and anaphylactic shock. Its product pipeline includes Sumatriptan, a novel the treatment of migraine which is in final stage of approval; Epinephrine/Adrenaline which is in Phase I clinical trial for the treatment of acute allergic reaction; a… Read more
Klaria Pharma Holding AB (KLAR) - Total Liabilities
Latest total liabilities as of December 2025: Skr44.65 Million SEK
Based on the latest financial reports, Klaria Pharma Holding AB (KLAR) has total liabilities worth Skr44.65 Million SEK as of December 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Klaria Pharma Holding AB - Total Liabilities Trend (2014–2025)
This chart illustrates how Klaria Pharma Holding AB's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Klaria Pharma Holding AB Competitors by Total Liabilities
The table below lists competitors of Klaria Pharma Holding AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
SAN-EL Muhendislik Elektrik Taahhut Sanayi ve Ticaret AS
IS:SANEL
|
Turkey | TL240.03 Million |
|
Essar Shipping Limited
NSE:ESSARSHPNG
|
India | ₹26.68 Billion |
|
Laser Photonics Corporation Common Stock
NASDAQ:LASE
|
USA | $13.36 Million |
|
Il Sung Const
KO:013360
|
Korea | ₩312.80 Billion |
|
Wentel Engineering Holdings Berhad
KLSE:0298
|
Malaysia | RM18.14 Million |
Liability Composition Analysis (2014–2025)
This chart breaks down Klaria Pharma Holding AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.05 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -11.50 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.10 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Klaria Pharma Holding AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Klaria Pharma Holding AB (2014–2025)
The table below shows the annual total liabilities of Klaria Pharma Holding AB from 2014 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Skr44.65 Million | -17.26% |
| 2024-12-31 | Skr53.96 Million | +69.62% |
| 2023-12-31 | Skr31.81 Million | -28.01% |
| 2022-12-31 | Skr44.19 Million | -9.62% |
| 2021-12-31 | Skr48.89 Million | +114.33% |
| 2020-12-31 | Skr22.81 Million | +16.29% |
| 2019-12-31 | Skr19.62 Million | +69.77% |
| 2018-12-31 | Skr11.55 Million | +391.91% |
| 2017-12-31 | Skr2.35 Million | +17.80% |
| 2016-12-31 | Skr1.99 Million | -13.04% |
| 2015-12-31 | Skr2.29 Million | +356.14% |
| 2014-12-31 | Skr502.69K | -- |